March 2026
Every article Wellness Radar published in March 2026 — long-form research, protocols, and reference work. Most-recent first.
Insulin resistance — the upstream signal everyone underrates
HOMA-IR vs HbA1c vs fasting insulin as early-warning markers. The dietary, training, and pharmacological levers with the strongest RCT support — and a tiered framework for using them.
The peptides worth knowing in 2026
Forty molecules get the hype, ten matter. A tiered map of the peptides with real human data in 2026 — what's established, what's promising, what's still speculative.
Circadian rhythm — light timing, body temperature, the master clock
How the SCN entrains, dose-response of morning bright light vs evening blue-light avoidance, core body temperature as master switch, DLMO timing, and a protocol stack with the strongest RCT support.
Tirzepatide vs Semaglutide: the head-to-head
SURMOUNT-5 head-to-head: tirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks. Mechanism, T2D data, side effects, cost, and where each drug still wins.
Metabolic syndrome — the 5 criteria and what each one signals
ATP-III and IDF criteria, what each of the five markers physiologically signals upstream, all-cause mortality risk per cluster count, and the intervention hierarchy from lifestyle to GLP-1 to surgery.
TRT in 2026: FDA's New Libido Indication and What It Changes
The FDA's April 2026 Federal Register notice (Docket FDA-2025-N-6743) signals a new TRT indication for idiopathic hypogonadism with low libido. What it means, how oral testosterone compares to injectable, enclomiphene…